Articles tagged with: Neupogen
News»
Good morning, myeloma world.
We have got quite an eclectic mix of myeloma-related research to report on today, ranging from a couple of lengthy review articles to a short case report.
Speaking of case reports, there are several of them, and we'll start with an unusual one. It's from a group of physicians at a hospital in Milan, Italy. They report on a patient with light chain monoclonal gammopathy who tested positive – incorrectly – on a standard test used to determine if someone regularly drinks a lot of alcohol (abstract). …
NewsFlash »
Velcade Receives Additional Approvals In Europe – The approved uses of Velcade (bortezomib) for multiple myeloma patients were recently expanded in the European Union. These additional approved uses include treatment of newly diagnosed transplant-eligible myeloma patients with Velcade plus dexamethasone (Decadron) or Velcade plus thalidomide (Thalomid) and dexamethasone, as well as retreatment of relapsed myeloma patients with Velcade for those who responded to prior Velcade therapy. Previously, Velcade was approved in combination with melphalan (Alkeran) and prednisone for the treatment of newly diagnosed myeloma patients who are ineligible for stem cell transplantation, or as a single agent for the treatment of relapsed myeloma patients with one prior therapy who have had a transplant or are ineligible for a transplant. For more information, please see the August 8 and June 28 Johnson & Johnson press releases about the new approvals for newly diagnosed and relapsed myeloma patients.
Pilot Clinical Trial To Test Whether Anti-Depressant Desipramine Assists With Stem Cell Mobilization – Researchers from the Albert Einstein College of Medicine in New York City have launched a clinical trial that will determine how well the antidepressant desipramine (Norpramin, Pertofrane) in combination with Neupogen (filgrastim), which is a type of granulocyte colony-stimulating factor (G-CSF), works to mobilize stem cells in multiple myeloma patients undergoing stem cell transplantation. A previous study in mice showed that desipramine plus G-CSF mobilized more stem cells than G-CSF alone. For more information about the study or how to enroll, see the clinical trial description.
Clinical Trial To Study Modified Version Of Melphalan Plus Dexamethasone For Relapsed / Refractory Myeloma – A new Phase 1/2 clinical trial is testing the efficacy and safety of a modified version of melphalan in combination with dexamethasone for relapsed and refractory myeloma patients. The modified version of melphalan, known as melphalan-flufenamide or melflufen, is being developed by the Swedish pharmaceutical company Oncopeptides and consists of melphalan bound to flufenamide. The drug only becomes active once it enters a cell and melphalan is released from flufenamide. Cancer cells more efficiently activate the drug, increasing the concentration of melphalan in cancer cells compared to healthy cells. The study is sponsored by Oncopeptides and is being conducted in the United States and Europe. For more information about the study or how to enroll, see the clinical trial description and related Oncopeptides press release.
News»
A recent retrospective study finds that initial treatment with Revlimid may not prevent myeloma patients from collecting enough stem cells for transplantation.
Many of the study's results confirm the findings of previous research, which has shown that Revlimid (lenalidomide) reduces a patient's ability to mobilize stem cells for stem cell collection (see related Beacon news).
However, only 2 percent of the patients in the new study were unable to mobilize enough stem cells for at least a single transplant, and this low overall rate of mobilization failure was the same in patients who …
News»
A recent study suggests that Mozobil helps multiple myeloma patients with prior exposure to Revlimid collect enough stem cells for transplantation.
The study investigators conclude that stem cell mobilization with the aid of a growth factor plus Mozobil (plerixafor) is an effective upfront approach for multiple myeloma patients who plan to undergo a transplant, regardless of previous Revlimid (lenalidomide) exposure.
“With growth factor and preemptive Mozobil, virtually all patients with multiple myeloma can have successful stem cell collection,” said Dr. Luciano Jose Costa of the Medical University of South Carolina, and …
News»
Results of a recent Italian study show that Neupogen and Neulasta are comparable in efficacy and safety for the prevention and treatment of low white blood cell counts in multiple myeloma patients receiving outpatient stem cell transplants.
However, patients who were treated with Neulasta only received one injection after the transplant, which according to the study authors may be more convenient for the patients.
“In our experience, the possibility of a single [injection] is more comfortable for patients, mainly in an outpatient regimen,” said Dr. Felicetto Ferrara of the Cardarelli Hospital in …
News»
Results of a recent Polish study show that the drug Mozobil may help multiple myeloma patients who previously had a stem cell transplant collect enough stem cells for a second transplant.
However, the results also showed that previously transplanted patients collected fewer stem cells than patients who had not received a stem cell transplant before.
According to the study authors, these results showed for the first time that Mozobil (plerixafor) is highly effective for previously transplanted myeloma patients.
Autologous stem cell transplantation, a common treatment option for younger, newly diagnosed myeloma …
News»
According to a recent study, omitting growth factor administration following stem cell transplantation results in fewer side effects and less and shorter hospitalization for multiple myeloma patients compared to those who do receive growth factors. In addition, the study authors found that there was little difference between the two groups in the repopulation of white blood cells following transplantation.
According to Dr. Morie Gertz, myeloma expert at the Mayo Clinic in Rochester, Minnesota and lead author of the study, the difference in the repopulation of white blood cells was not clinically significant. …
